nds,
c Older the leadership of
Dear Ctie To Zionist Oisanization of Arasica,

Iskorton 1Ceirt, has done important work. is entioill% israds caSe to

eVosir.4 arld

the Nat:iota riblic., media and Coness,
by
Oslo abyssby
formed t vital $ervico
1ping,
has per
asald by teests
f the
A
'the Z.0
challensing the ? 1,SY s vlolations o
documenting and combatins imi-Iscael media bi; z
Mau-loans understand t)ac bared values 241:4100131 tategic, intet

basiS oiU.S.-Israel Irlend.04.

you to support the ZON and its efforts on bezalf of

t11,2/, to the

1 %AV

Israek.

I want to help the ZOA help Israel

I am enclosing my annual membership dues:

Family Membership $50
Senior or Student $36

Bill me:
Patron $180
Builder $150

• Clinical Teaching
• Testing/Evaluation
• Therapeutic Tutoring

545-6677 • 433-3323

Oak Park

LYNNE MASTER, M.Ed

Owner Director

Bloomfield Hills

http://www.metroguide.com/lynne

$100
Sustainer
Life Membership $1000

Dr. Benjamin Sredni talks about his work.

mmune To The Effects

An Israeli scientist takes the road less traveled to a
discovery which may help in treating cancer.

JILL DAVIDSON SKLAR STAFF WRITER

r. Benjamin Sredni knows
the immune system per-
haps better than most peo-
ple.
For-the past 20 or so years he
has tinkered in laboratories, first
cloning T-lymphocyte cells, then
synthesizing new compounds that
protect the immune system from
the chemotherapy's dreadful ef-
fects.
Now the dean of natural life sci-
ences and mathematics at Bar-
Ean University in Israel, the
Mexican-born scientist is putting
the immunomodulating drug,
AS101, through clinical trials to
test if— when used in conjunction
with potentially devastating
chemotherapeutic drugs — it pro-
tects the bone marrow of cancer
patients.
A recent finding of his, pub-
lished in the Journal of Clinical
Oncology, showed promising re-
sults. The drug will now enter a
third phase of testing, part of a
process to declare it safe under
Food and Drug Administration
guidelines.
"We are very aggressive [in
treating tumors]. We kill the tu-
mor cells but we also kill the im-
mune system," he said, adding
that this protocol then leaves the
patient susceptible to a host of po-
tentially fatal infections.
Dr. Sredni came to his discov-
ery of the compound while follow-
ing the scientific world's
equivalent of the road less trav-
eled. After his first article on the
cloning appeared in 1979 in the
scientific journal Nature, he de-
cided his next project would veer
from the usual to the unusual,
which then led to the synthesis of
the compound and its testing.
"You need to be a little more

imaginative to do something
maybe illogical because this is the
way to do something new," he said,
taking a break from a recent sem-
inar series he delivered at the Na-
tional Institute of Health in
Bethesda, Md. 'The logical is al-
ready done."
But while he has had consider-
able success in the scientific are-
na, he has learned that some
aspects of treating disease are be-
yond the grasp of new drugs or of
different protocols.
In treating some of the patients
in his study, he often found that
some of the lesser effected indi-
viduals fared worse than the sick-
er subjects. In talking with the
research subjects, he found those
who did the best were more up-
beat, more positive in their ap-
proach to treatment and living life.
`Their attitude will make all of
the difference," he said. ❑

OT
SHOT

I

111167NEMTEND

The Tri-County Orthopedic
Group, P.C., is pleased to an-
nounce the association of Dr.
Miles L. Singer, a general or-
thopedist and fellowship-trained

surgeon.
Dr. Singer's fellowship was fin-
ished in July at Southern Illinois
University. Prior to that, he com-
pleted his residency and intern-
ship at Botsford Hospital in CZ
Farmington. He is a graduate of
the College of Osteopathic Medi-
cine and Surgery in Des Moines,